E-MAIL: your-email@mail.com
E-MAIL: your-email@mail.com
Johnson & Johnson’s MONARCH Platform helps improve early lung cancer detection by enabling physicians to access and biopsy suspicious lung nodules that are difficult to reach with conventional bronchoscopy.
imphoenix82
Firefly Bio’s Firelink DAC platform will help advance Johnson & Johnson’s strategy to develop targeted therapies for some of the most prevalent and difficult-to-treat solid tumours.
imphoenix82
Johnson & Johnson’s RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj) is currently approved in more than 40 countries, including the US, Europe and Japan, for the subcutaneous treatment of non-small cell lung cancer.
imphoenix82
Johnson & Johnson plans a phased commercial rollout of the OTTAVA system with select customers in the United States while working in parallel to advance into additional indications.
imphoenix82
Johnson & Johnson said the CHMP opinion is an important step towards positioning the off-the-shelf immunotherapy combination of teclistamab and daratumumab as a potential new standard of care earlier in the multiple myeloma treatment pathway.
imphoenix82HealthXplore is a digital platform dedicated to delivering insights into what’s new and what’s next in healthcare, pharmaceuticals, and medical innovation. We aim to bridge the gap between complex industry developments and informed audiences by presenting credible, timely, and engaging content.
Contact: +91 9354115542
HealthXploreIndia @2026. All Rights Reserved.
